




Development of a Neutralizing Antibody Assay for Anti-Drug Antibodies (ADA) Against a Fusion Molecule

The molecule is a fusion protein


The molecule is a fusion of cancer-specific apoptosis inducing ligand (Apo2L/TRAIL) with a peptide binding to VEGFR



Double targeting

- binding to DR4 and DR5 receptors on cancer cells – apoptosis induction
- binding to VEGFR – inhibition of angiogenesis

Strategy for NAb assay development



	MoA		Test system	
1	Activation of DR is down or hyperactivation is on (4)	Apoptosis	MTT assay in one of the cell lines: A549/HepG2/SK-Mes1	Need for differentiation between two phenomena. Moderately sensitive cell line should show both decreased or increased activity
2	Bypassing TRAIL-resistance is lost			In case the test molecule is neutralized it will become ineffective in TRAIL-resistance cell lines
3	VEGFR	Binding to receptor	Binding assay	Detection of the test molecule binding to VEGFR by SPR method